Table 3.
Association of cardiac biomarkers with CV mortality
| Cardiac biomarker | Model 0 |
Model 1 |
Model 2 |
Model 3 (combined analysis) |
||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | HR (95% CI) | P value | |
| CV mortality | ||||||||
| Log(NT-proBNP) per 1 SD (1.71) increase | 2.66 (2.35, 3.00) | <0.0001 | 2.10 (1.80, 2.45) | <0.0001 | 2.04 (1.74, 2.39) | <0.0001 | 1.89 (1.60, 2.22) | <0.0001 |
| Log(hsTnT) per 1 SD (0.82) increase | 2.12 (1.94, 2.31) | <0.0001 | 1.87 (1.65, 2.11) | <0.0001 | 1.82 (1.60, 2.06) | <0.0001 | 1.71 (1.50, 1.95) | <0.0001 |
| Log(GDF-15) per 1 SD (0.59) increase | 2.22 (2.01, 2.45) | <0.0001 | 1.63 (1.41, 1.89) | <0.0001 | 1.55 (1.33, 1.81) | <0.0001 | 1.44 (1.23, 1.68) | <0.0001 |
| Log(sST-2) per 1 SD (0.56) increase | 1.50 (1.34, 1.67) | <0.0001 | 1.27 (1.11, 1.44) | 0.0004 | 1.22 (1.08, 1.39) | 0.002 | 1.13 (1.00, 1.27) | 0.04 |
CI, confidence interval; CV, cardiovascular; GDF-15, growth differentiation factor−15; HR, hazard ratio; hsTnT, high-sensitivity troponin T; NT-proBNP, N-terminal pro-B-type natriuretic peptide; sST-2, soluble ST-2.
Model 0: unadjusted. Model 1: age, sex, race/ethnicity, site, diabetes, cardiovascular disease, body mass index, smoking, systolic blood pressure, low-density lipoprotein, high-density lipoprotein, estimated glomerular filtration rate, log-transformed 24-hour urinary protein.. Model 2: Model 1 + fibroblast growth factor−23, phosphorus, β-blockers, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, diuretics. Model 3: Model 2 + alternative cardiac biomarker.